[email protected]   +1 (304) 470-2225

Signaling Regulatory Protein (SIRP) α Inhibitors – Pipeline Analytics 2021

$2,500.00$7,500.00

Signaling Regulatory Protein (SIRP) α Inhibitor’s report covers the SIRP α market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, and therapy area. SIRP α inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.

Clear
SKU: MM202040 Category:

Description

Signaling Regulatory Protein (SIRP) α Inhibitors are currently considered to be among the most sought-after phagocytosis checkpoints in anti-tumor therapeutic development which has generated a great amount of interest among companies to develop an emerging class of immuno-oncology drugs that target “don’t eat me” signaling, which is a strategy used by tumors to escape immune destruction. Currently, multiple therapeutic biologicals are under development targeting CD47-SIRPα protein in different developmental phases and therapy areas like oncology, autoimmune and CNS diseases with approximately 20 candidates currently under evaluation in clinical and preclinical studies.

The report provides an in-depth analysis of key pipeline products by segments like Stage of development, Company and Therapy Area. It also provides the in-depth analysis of licensing, acquisition and collaborations deals. The comprehensive information provided by Mellalta Meets in this report will also help companies in identifying better opportunities and expanding their research in different therapy area via target CD47-SIRPα axis.

As per Mellalta Meets analysis, the development pipeline is full of directly acting specific and bispecific SIRPα inhibitors or indirect modulators of the CD47-SIRPα pathway consisting of molecules like monoclonal antibodies, fusion proteins, and small molecules. At least 20 distinct molecules targeting the CD47-SIRPα pathway are in clinical development. Clinical and regulatory timelines of later stage products like Magrolimab (Gilead Sciences /Forty Seven), a humanized anti-CD47 monoclonal antibody known as hu5F9-G4 and RRx-001 (EpicentRx/RadioRx) are the major highlights of the report along with description of their clinical trial analysis.

Key Highlights of Signaling Regulatory Protein (SIRP) α Inhibitors Report

  • There are ~9 products in the Phase-I stage of development, representing 45% of the total share of the developing SIRPα inhibitors landscape.

SIRP a Inhibitors - Pipeline landscape

  • The pipeline of SIRPα is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~50% of all the pipeline SIRPα in clinical stages.
  • Oncology represents ~ 90% of the total SIRPα therapies while the therapy areas namely Autoimmune Diseases, and CNS Disease occupy the remaining 10% of the SIRPα trials.
  • To be continued…

Report Coverage:

  • Indication Prioritisation: Signaling Regulatory Protein (SIRP) α market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • Signaling Regulatory Protein (SIRP) α Pipeline Development: Product Profiles, Clinical Trials & Results
  • Signaling Regulatory Protein (SIRP) α Acquisition Targets
  • Signaling Regulatory Protein (SIRP) α Competitive Intelligence
  • Recent & Upcoming events

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • SIRPα Inhibitors Report Overview
  • The Signaling Regulatory Protein (SIRP) α Target BACKGROUND
    • Signaling Regulatory Protein (SIRP) alpha Overview
    • Advances in Anti-Tumor Treatments Targeting the SIRPα
    • Relationship Between SIRPα Signaling Pathways and Diseases
  • Signaling Regulatory Protein (SIRP) α PIPELINE ANALYSIS
    • Pipeline Products by Stage of Development
    • Signaling Regulatory Protein (SIRP) α Competitive Landscape
    • Pipeline Products by Company
    • Pipeline Products by Therapy Area
    • Signaling Regulatory Protein (SIRP) α Clinical & Regulatory Timelines
  • Signaling Regulatory Protein (SIRP) α LICENSING, ACQUISITION AND COLLABORATION DEALS
    • Signaling Regulatory Protein (SIRP) α Licensing, Acquisition and Deal values
    • Signaling Regulatory Protein (SIRP) α Licensing by Transaction type and Total amount size by stages of development
  • Signaling Regulatory Protein (SIRP) α Inhibitors – Pipeline Landscape
    • Profile Comparisons At–a–glance
    • SIRP α PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
      • Phase III Products
        • Gilead Sciences /Forty Seven: Magrolimab
          • Product Profile & Description
          • Clinical Trials
        • EpicentRx/RadioRx: RRx-001
          • Product Profile & Description
          • Clinical Trials
      • Phase II Products
        • ALX Oncology: ALX-148
          • Product Profile & Description
          • Clinical Trials
        •  Vivoryon Therapeutics: Varoglutamstat
          • Product Profile & Description
          • Clinical Trials
      • Phase I/II Products
        • KAHR medical: DSP-107
          • Product Profile & Description
          • Clinical Trials
      • Phase I/II Products
        • CSPC Pharmaceutical Group Co./Conjupro Biotherapeutics: JMT-601
          • Product Profile & Description
          • Clinical Trials
        •  Bristol-Myers Squibb/Celgene:CC-95251
          • Product Profile & Description
          • Clinical Trials
        • Gilead Sciences, Inc./Forty Seven: FSI-189
          • Product Profile & Description
          • Clinical Trials
        • ImmuneOnco Biopharma: IMM-01
          • Product Profile & Description
          • Clinical Trials
        • OSE Therapeutics SA: OSE-172
          • Product Profile & Description
          • Clinical Trials
        • Shattuck Labs:SL-172154
          • Product Profile & Description
          • Clinical Trials
        • Surface Oncology: Urabrelimab
          • Product Profile & Description
          • Clinical Trials
  • SIRP α PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
    • Phase I/II
          • Chia Tai Tianqing Pharmaceutical Group Co: TQB-2928
            • Product Profile & Description
            • Clinical Trials
          •  Trillium Therapeutics Inc: Ontorpacept
            • Product Profile & Description
            • Clinical Trials
          • Trillium Therapeutics Inc: TTI-622
            • Product Profile & Description
            • Clinical Trials
  • Preclinical
          • Aduro BioTech: ADU-1805
            • Product Profile & Description
            • Clinical Trials
          • Compass Therapeutics, Inc: CTX-5861
            • Product Profile & Description
            • Clinical Trials
          • Electra Therapeutics: ELA026
            • Product Profile & Description
            • Clinical Trials
  • SIRP α PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS
    • Preclinical
          • Alector/Innovent Biologics: AL-008
            • Product Profile & Description
            • Clinical Trials
          • Byondi B.V: BYON4228
            • Product Profile & Description
            • Clinical Trials
  • SWOT Analysis
  • Appendix

Companies Coverage

  • Aduro BioTech, Inc.
  • Alector/Innovent Biologics
  • ALX Oncology
  • Bristol-Myers Squibb/Celgene
  • Byondi B.V
  • Chia Tai Tianqing Pharmaceutical Group Co.
  • Compass Therapeutics, Inc.
  • CSPC Pharmaceutical Group Co./Conjupro Biotherapeutics
  • Electra Therapeutics, Inc.
  • EpicentRx, Inc./RadioRx
  • Gilead Sciences Inc./Forty Seven
  • ImmuneOnco Biopharma Co.,Ltd.
  • KAHR medical
  • OSE Therapeutics SA
  • Shattuck Labs
  • Surface Oncology
  • Trillium Therapeutics Inc
  • Vivoryon Therapeutics
  • Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going